Theriva Biologics (TOVX)

• Market cap: $13.5M
• 1 day: -3.23%
• 5 days: 14.17%
• 1 month: 1.03%
• 3 months: 52.41%
• 6 months: 49.69%
• Year to date: 13.95%
• 1 year: -37.06%
• 5 years: -99.81%
• 10 years: -100%
• Sector: Healthcare
• Industry: Drug Manufacturers - General

About: Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system. Product Candidates includes SYN-004 (ribaxamase) and SYN-020.

Employees: 16